LI-RADS 2018版治疗反应算法:肝细胞癌经动脉放射性栓塞治疗后的诊断性能
回顾性纳入2011年1月至2019年12月接受经动脉放射性栓塞后行肝脏手术的27例患者34个病灶,以病理坏死程度为参考标准。三位放射科医师独立评估LI-RADS 2018版治疗反应算法,LR-TR非存活类别预测完全坏死的敏感度73.3-80.0%、特异度78.9-89.5%,LR-TR存活类别预测不完全坏死的敏感度73.7-79.0%、特异度93.3-100%。
要点
- LR-TR非存活类别预测完全坏死的敏感度73.3-80.0%,特异度78.9-89.5%。
- LR-TR存活类别预测不完全坏死的敏感度73.7-79.0%,特异度93.3-100%。
- 34个病灶中5个(14.7%)被共识归为LR-TR不确定,其中2个病理为不完全坏死。
核心结论
- LI-RADS 2018版治疗反应算法可用于预测经动脉放射性栓塞治疗的肝细胞癌的组织病理学活性。
研究设计与样本
- 回顾性研究,纳入2011年1月至2019年12月接受经动脉放射性栓塞后行肝脏手术的27例患者(平均年龄±标准差55.9±9.1岁;24例男性)共34个病灶,以肝脏手术组织病理学为参考标准(完全坏死15个、不完全坏死19个),三位放射科医师独立审阅治疗前后CT或MR图像。
诊断标准与关键数值
- LR-TR非存活类别预测完全坏死:敏感度73.3-80.0%,特异度78.9-89.5%;LR-TR存活类别预测不完全坏死:敏感度73.7-79.0%,特异度93.3-100%;LR-TR类别读者间一致性Fleiss κ=0.81(95%CI:0.66-0.96)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 treatment response algorithm (TRA) for the evaluation of hepatocellular carcinoma (HCC) treated with transarterial radioembolization.
MATERIALS AND METHODS: This retrospective study included patients who underwent transarterial radioembolization for HCC followed by hepatic surgery between January 2011 and December 2019. The resected lesions were determined to have either complete (100%) or incomplete (< 100%) necrosis based on histopathology. Three radiologists independently reviewed the CT or MR images of pre- and post-treatment lesions and assigned categories based on the LI-RADS version 2018 and the TRA, respectively. Diagnostic performances of LI-RADS treatment response (LR-TR) viable and nonviable categories were assessed for each reader, using histopathology from hepatic surgeries as a reference standard. Inter-reader agreements were evaluated using Fleiss κ.
RESULTS: A total of 27 patients (mean age ± standard deviation, 55.9 ± 9.1 years; 24 male) with 34 lesions (15 with complete necrosis and 19 with incomplete necrosis on histopathology) were included. To predict complete necrosis, the LR-TR nonviable category had a sensitivity of 73.3-80.0% and a specificity of 78.9-89.5%. For predicting incomplete necrosis, the LR-TR viable category had a sensitivity of 73.7-79.0% and a specificity of 93.3-100%. Five (14.7%) of 34 treated lesions were categorized as LR-TR equivocal by consensus, with two of the five lesions demonstrating incomplete necrosis. Inter-reader agreement for the LR-TR category was 0.81 (95% confidence interval: 0.66-0.96).
CONCLUSION: The LI-RADS version 2018 TRA can be used to predict the histopathologic viability of HCCs treated with transarterial radioembolization.
引用
- Yoon J, Lee S, Shin J, et al. LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma. Korean J Radiol. 2021. PMID: 33987991. doi:10.3348/kjr.2020.1159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。